

Longenesis and business angels led by Rustam Gilfanov close \$1.2 million late seed round



New York, New York City, Jun 28, 2021 ([Issuewire.com](https://www.issuewire.com)) - Longenesis has raised \$1.2 million in a late seed round led by Rustam Gilfanov and supported by a group of business angels. Ilya Suharenko, a private investor and one of LongeVC's Managing Partners, also participated in the round providing 17 years of his expertise in finance.

Longenesis is engaged in developing and implementing tools to accelerate biomedical research in digitalization. Its major goal is to promote patients' participation and confidence in research organizations and study sponsors, as well as to allow clinical sites and patient advocacy groups to legally submit data on their patients to a wide range of biomedical researchers.

Medical data is sensitive and private; thus, it is one of the most challenging for researchers who want to have a lot of thorough datasets. Longenesis will assist in cutting recruiting costs and speeding up biomedical research by integrating digitalization and consent-enabled exhibiting of biological assets, as well as emphasizing patient-centricity.

Longenesis will use the money raised to grow in its key areas and scale up the deployment of its main

products. Longenesis offers three main products:

Longenesis Curator

Curator enables such research institutions as hospitals and biobanks to publish anonymized patient records and get requests for cooperation directly from study sponsors.

Patient confidentiality is assured since the data does not include any personally identifying information. However, the data-enhanced display and accessibility enable third parties to quickly assess if such data is relevant to their research projects and at the same time speed up what was previously a difficult, sluggish, expensive, and time-consuming process. This allows tailored data to be used for research while respecting privacy and adhering to regional regulatory requirements.

Researchers from universities, government organizations, and AI businesses may access the data for sophisticated studies.

Longenesis Themis

For onboarding participants in biomedical research and clinical trials, Themis offers an API-based consent management platform. This allows for complete patient-centricity and encourages patients to take an active position in research projects and have a greater understanding of their position.

“Flexible digital consent enables research participants to take control over their participation in the research by calmly reading the informed consent document and signing or rescinding it at any moment. People’s faith in academics and science as a whole grows as a result of this chance,” Lilian Tzivian, Ph.D., a senior epidemiologist at the University of Latvia, says.

Longenesis Engage

With a simple click on the research organization link, *Engage* makes onboarding new patients very simple.

Engage also handles patients’ contact information for follow-up inquiries and keeps track of their permissions throughout their participation in scientific studies. It also includes facilities for exporting and monitoring data, allowing for analysis during the clinical trial.

Longenesis traction

In the EU, the Middle East, and Asia, Longenesis has already implemented its solutions with a variety of governments, biopharmaceutical firms, and academic consortia by offering data curation and patient contact services.

In addition, the business has established a collaboration with Medtronic. The Medtronic-Longenesis collaboration, which also includes diabetic patient groups, will serve as a testbed for incorporating digital patient interaction into research and advocacy efforts.

“Advocacy is an important component of the patient organization’s mission, but it has also been a big battle up until now. We need to involve patients in a continuous discussion to ensure that their needs and wants are taken seriously and that their best interests are prioritized. Many things obstruct this process including their different capacities and the skepticism that comes with any chronic illness. As a

result, we are thrilled to work with Longenesis. We feel that their patient engagement and data curation solutions will provide us with essential access to diabetes patients, as well as research partners who may be able to assist them. The current research, as we hope, is only the beginning,” Indra Stelmane, Ph.D., a leading endocrinologist and the President of the Latvian Diabetes Federation, says.

Longenesis supporters

LongeVC is a driving factor behind Longenesis. LongeVC is an investment fund that focuses on industrial development, financing, and start-up development for biotech firms.

LongeVC fundamentally emphasizes finding startups in cutting-edge technology sectors of the longevity business. LongeVC’s Managing Partner, Garri Zmudze, says:

“For any biotech or longevity-focused enterprise, compliant access to clinical data and patient cohorts will remain a critical success component. In the future years, we think, Longenesis has what it takes to become a backbone of compliant biomedical data usage.”

Rustam Gilfanov, a business angel and Venture Partner at the LongeVC investment fund, who led the investment round, spoke on the importance of digitalization in biotechnology and medical research:

“Biotechnology is quickly evolving nowadays, with formerly totally human-dependent and too laborious procedures becoming digitalized. Recent AI-driven drug discovery achievements are a marvelous illustration of this, and there will be many more in the future. For such advances to be repeatable and scalable, digitalization, transparency, and compliance in biological data asset access are essential. The fund aims to help such businesses grow. This is the way things are going to be in the future.”

Media Contact

Blacklight

volodya.sidorov.2001@list.ru

Source : Longenesis

[See on IssueWire](#)